Morgan Stanley raised the firm’s price target on Personalis (PSNL) to $9 from $5 and keeps an Equal Weight rating on the shares after the company announced Medicare coverage of its ultrasensitive NeXT Personal test for surveillance of cancer recurrence in breast cancer patients.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis price target raised to $12 from $6 at Guggenheim
- Personalis price target raised to $13 from $10 at H.C. Wainwright
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- Personalis Secures Medicare Coverage for NeXT Personal MRD Test, Positioning for Growth in Underpenetrated $20 Billion Market
- Personalis Gains Medicare Coverage for Cancer Test